Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis

[1]  Z. Israel,et al.  Reversing a Model of Parkinson's Disease With In Situ Converted Nigral Neurons , 2020, Movement disorders : official journal of the Movement Disorder Society.

[2]  R. Stavely,et al.  The emerging antioxidant paradigm of mesenchymal stem cell therapy , 2020, Stem cells translational medicine.

[3]  J. Galipeau,et al.  Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match. , 2020, Blood advances.

[4]  B. Jones,et al.  Classifying Amyotrophic Lateral Sclerosis Patients by Changes in Forced Vital Capacity: A Group-Based Trajectory Analysis. , 2019, American journal of respiratory and critical care medicine.

[5]  S. Wilton,et al.  ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? , 2019, Front. Neurosci..

[6]  Shawn P. Driscoll,et al.  Spinal parenchymal occupation by neural stem cells after subpial delivery in adult immunodeficient rats , 2019, Stem cells translational medicine.

[7]  N. Staff,et al.  NurOwn, phase 2, randomized, clinical trial in patients with ALS , 2019, Neurology.

[8]  F. Fang,et al.  Epidemiology of amyotrophic lateral sclerosis: an update of recent literature , 2019, Current opinion in neurology.

[9]  M. Copetti,et al.  Results from Phase I Clinical Trial with Intraspinal Injection of Neural Stem Cells in Amyotrophic Lateral Sclerosis: A Long‐Term Outcome , 2019, Stem cells translational medicine.

[10]  A. Vercelli,et al.  Transplantation of clinical-grade human neural stem cells reduces neuroinflammation, prolongs survival and delays disease progression in the SOD1 rats , 2019, Cell Death & Disease.

[11]  A. Chiò,et al.  Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials , 2019, Neurology.

[12]  S. Appel,et al.  Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies , 2019, The Lancet Neurology.

[13]  A. Zajícová,et al.  Immunomodulatory Properties of Bone Marrow Mesenchymal Stem Cells from Patients with Amyotrophic Lateral Sclerosis and Healthy Donors , 2018, Journal of Neuroimmune Pharmacology.

[14]  C. Ki,et al.  Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis , 2018, Annals of neurology.

[15]  A. Sarnowska,et al.  Intraspinal Transplantation of the Adipose Tissue-Derived Regenerative Cells in Amyotrophic Lateral Sclerosis in Accordance with the Current Experts' Recommendations: Choosing Optimal Monitoring Tools , 2018, Stem cells international.

[16]  S. Hosseini,et al.  Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial , 2018, Cell journal.

[17]  A. Sarnowska,et al.  Advances in stem cell therapy for amyotrophic lateral sclerosis , 2018, Expert opinion on biological therapy.

[18]  I. Vorisek,et al.  Transplantation of Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial , 2017, Cell transplantation.

[19]  Robert H. Brown,et al.  Decoding ALS: from genes to mechanism , 2016, Nature.

[20]  Parag G. Patil,et al.  Transplantation of spinal cord–derived neural stem cells for ALS , 2016, Neurology.

[21]  C. Heyser,et al.  Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs , 2016, Neuron.

[22]  E. Melamed,et al.  Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. , 2016, JAMA neurology.

[23]  J. Ravits,et al.  Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. , 2015, Neurologic clinics.

[24]  Hyun Young Kim,et al.  Phase I Trial of Repeated Intrathecal Autologous Bone Marrow‐Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis , 2015, Stem cells translational medicine.

[25]  A. Sharma,et al.  The effect of autologous bone marrow mononuclear cell transplantation on the survival duration in Amyotrophic Lateral Sclerosis - a retrospective controlled study. , 2015, American journal of stem cells.

[26]  D. Brat,et al.  Analysis of graft survival in a trial of stem cell transplant in ALS , 2014, Annals of clinical and translational neurology.

[27]  Wei Cao,et al.  Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications , 2014, Nature Immunology.

[28]  Yasuto Itoyama,et al.  Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[29]  S. Koh,et al.  Biological Markers of Mesenchymal Stromal Cells as Predictors of Response to Autologous Stem Cell Transplantation in Patients With Amyotrophic Lateral Sclerosis: An Investigator‐Initiated Trial and In Vivo Study , 2014, Stem cells.

[30]  J. Glass,et al.  Intraspinal Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: Phase 1 Trial Outcomes , 2014, Annals of neurology.

[31]  M. Swash,et al.  Does surgery accelerate progression of amyotrophic lateral sclerosis? , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[32]  S. Donato.  Faculty Opinions recommendation of An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. , 2013 .

[33]  A. Pestronk,et al.  An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study , 2013, The Lancet Neurology.

[34]  S. Sheen,et al.  Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. , 2013, Journal of clinical epidemiology.

[35]  C. Antunez,et al.  Neurotrophic Bone Marrow Cellular Nests Prevent Spinal Motoneuron Degeneration in Amyotrophic Lateral Sclerosis Patients: A Pilot Safety Study , 2012, Stem cells.

[36]  M. Gunetti,et al.  Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial , 2010, Experimental Neurology.

[37]  A. Caplan.  Why are MSCs therapeutic? New data: new insight , 2009, The Journal of pathology.

[38]  A. Vercelli,et al.  Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis , 2008, Neurobiology of Disease.

[39]  L. Mazzini,et al.  Stem cell treatment in Amyotrophic Lateral Sclerosis , 2008, Journal of the Neurological Sciences.

[40]  T. Siddique,et al.  Presence of dendritic cells, MCP‐1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue , 2004, Annals of neurology.

[41]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[42]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[43]  T. Ben-Hur,et al.  Safety and Clinical Effects ofMesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in PatientsWith Amyotrophic Lateral Sclerosis Results of Phase 1 / 2 and 2 a Clinical Trials , 2016 .

[44]  Eugenio Gutiérrez-Jiménez,et al.  Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. , 2009, Cytotherapy.

[45]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[46]  James D. Frost,et al.  Long-Term Outcome , 2003 .